Recent updates on the role of microRNAs in prostate cancer.
Recent updates on the role of microRNAs in prostate cancer.
复制标题
DOI：
10.1186/1756-8722-5-9
复制
发表时间：
2012-03-14
影响因子：
28.5
通讯作者：
Sarkar FH
中科院分区：
文献类型：
--
作者：
Hassan O;Ahmad A;Sethi S;Sarkar FH
MicroRNAs(MiRNAs)是一种短小的非编码RNA，通过转录后调控基因参与几个重要的生物学过程。癌变是miRNAs在基因调控中发挥重要作用的关键生物学过程之一。MiRNAs通过与其目标mRNAs的3‘非翻译区(3’UTR)结合而产生作用，导致翻译的抑制或mRNA的降解，这取决于互补碱基配对的程度。到目前为止，假设存在1000多个miRNAs，尽管该领域正在迅速发展。目前，miRNAs正在成为许多研究领域的兴趣中心，特别是在肿瘤学方面，正如过去十年出版的指数增长所证明的那样。这些研究表明，在各种各样的人类癌症中，miRNAs被解除了调控。因此，有理由提出这样一个问题：进一步了解miRNAs的作用是否有助于前列腺癌(PCa)的诊断、预后和预测疗效。因此，在这篇综述文章中，我们将讨论不同miRNAs在前列腺癌中的潜在作用，以提供最新信息，以期在不久的将来促进该领域的进一步研究，以实现miRNA靶向治疗转移性去势耐药前列腺癌(MCRPC)的好处，因为目前mCRPC尚无根治性治疗方法。
MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biological processes through regulation of genes post-transcriptionally. Carcinogenesis is one of the key biological processes where miRNAs play important role in the regulation of genes. The miRNAs elicit their effects by binding to the 3' untranslated region (3'UTR) of their target mRNAs, leading to the inhibition of translation or the degradation of the mRNA, depending on the degree of complementary base pairing. To-date more than 1,000 miRNAs are postulated to exist, although the field is moving rapidly. Currently, miRNAs are becoming the center of interest in a number of research areas, particularly in oncology, as documented by exponential growth in publications in the last decade. These studies have shown that miRNAs are deregulated in a wide variety of human cancers. Thus, it is reasonable to ask the question whether further understanding on the role of miRNAs could be useful for diagnosis, prognosis and predicting therapeutic response for prostate cancer (PCa). Therefore, in this review article, we will discuss the potential roles of different miRNAs in PCa in order to provide up-to-date information, which is expected to stimulate further research in the field for realizing the benefit of miRNA-targeted therapeutic approach for the treatment of metastatic castrate resistant prostate cancer (mCRPC) in the near future because there is no curative treatment for mCRPC at the moment.
登录
查看更多内容
影响因子：
64.8
作者：
Cullen, Bryan R.
通讯作者：
Cullen, Bryan R.
影响因子：
11.2
作者：
Ahmad A;Aboukameel A;Kong D;Wang Z;Sethi S;Chen W;Sarkar FH;Raz A
通讯作者：
Raz A
影响因子：
6.4
作者：
Brase, Jan C.;Johannes, Marc;Sueltmann, Holger
通讯作者：
Sueltmann, Holger
影响因子：
7.8
作者：
Dick, J E
通讯作者：
Dick, J E
影响因子：
64.8
作者：
Denli, AM;Tops, BBJ;Hannon, GJ
通讯作者：
Hannon, GJ